Leerink raised the firm’s price target on BridgeBio to $86 from $75 and keeps an Outperform rating on the shares. Heading into 2026, the firm is refreshing its TTR market outlook after strong launches from BridgeBio’s (BBIO) Attruby and Alnylam’s (ALNY) Amvuttra. Leerink expects continued robust growth in 2026, supported by end-market tailwinds from improved diagnosis rates leading to earlier treatment, but is keeping tabs on payer/reimbursement dynamics and pace of new patient adds/switches.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- PayPal downgraded, Roku upgraded: Wall Street’s top analyst calls
- BridgeBio initiated with an Outperform at Bernstein
- BridgeBio Pharma: Buy Rating Backed by Promising Drug Pipeline and Strategic Market Positioning
- BridgeBio presents BBO-10203 data at San Antonio Breast Cancer Symposium
- BridgeBio price target raised to $84 from $76 at Wells Fargo